About the Journal

Perspective in Oncology Management and Research (POMR) is a prestigious international, peer - reviewed, open - access journal dedicated to oncology. Our core mission is to offer a top - tier platform for scientists, clinicians, and researchers to share their state - of - the - art experimental and theoretical findings. We emphasize transparency and reproducibility, urging authors to provide full experimental details for others to replicate and expand on their work. The journal is published online semiannually by Cultech Publishing Sdn. Bhd.

Aim and Scope
The aim and scope of the journal includes, but is not limited to, the following areas:

Molecular and Genomic Oncology

  • Pathway analyses and signaling networks in tumor initiation and progression
  • Role of non-coding RNAs (e.g., miRNAs, lncRNAs) in cancer biology and therapy
  • Epigenetic mechanisms (DNA methylation, histone modification) in carcinogenesis and treatment resistance
  • Cancer genetics, including hereditary cancer syndromes and germline mutations

Liquid Biopsy and Early Detection

  • Circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes as biomarkers for early diagnosis, prognosis, and monitoring
  • Advances in liquid biopsy technologies for minimal residual disease detection and treatment response assessment

Tumor Heterogeneity and Cancer Stem Cells

  • Molecular characterization of cancer stem cells and their role in metastasis, recurrence, and therapy resistance
  • Strategies targeting tumor-initiating cells to improve treatment outcomes

Tumor Immunology and Immunotherapy

  • Immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines
  • Mechanisms of immune evasion and strategies to overcome resistance
  • Interactions between the tumor microenvironment and immune cells

Tumor Microenvironment and Metastasis

  • Role of stromal cells, extracellular matrix, and metabolic reprogramming in tumor progression
  • Angiogenesis, hypoxia, and inflammation in cancer development

Targeted Therapies and Precision Oncology

  • Novel small-molecule inhibitors, monoclonal antibodies, and combination therapies
  • Overcoming drug resistance through rational drug design and repurposing strategies

Clinical Oncology and Translational Research

  • Phase I-III clinical trials evaluating new therapeutic agents or regimens
  • Real-world evidence studies on treatment patterns, outcomes, and health economics
  • Cancer risk screening, prevention, and survivorship care

Interdisciplinary and Emerging Fields

  • Nanotechnology, AI, and machine learning in cancer diagnosis and treatment optimization
  • Studies integrating basic, clinical, and population-level data to improve cancer care

Open Access: This journal operates under a "gold" Open Access model, providing free access to all readers.  The Article Processing Charges (APC) for all article types (research, review, case reports) is $0, and the content will be published under a CC BY 4.0 license. To encourage submissions and support the research community, POMR currently levies no APC (0 APC). For specific APC policies, please refer to the Open Access Policies.

General Information

    1st Year Published: 2026

    Frequency: Semiannually

    Issues Per Year: 2

    Country / Region: Malaysia

    Primary Language: English

    Publisher Information: Cultech Publishing Sdn. Bhd.